Lake Street Initiates Coverage On Spruce Biosciences with Buy Rating, Announces Price Target of $149
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsInitiationPrice Target
Lake Street analyst Daniel Brims initiates coverage on Spruce Biosciences (NASDAQ:SPRB) with a Buy rating and announces Price Target of $149.
Lake Street analyst Daniel Brims initiates coverage on Spruce Biosciences (NASDAQ:SPRB) with a Buy rating and announces Price Target of $149.